Medicare Lowers Payments For 340B Drugs: Promising Sign For Further Reform?
PhRMA is stepping up its advocacy for 340B reform, noting recent reduction in Medicare payments for 340B is encouraging in that it indicates Administration may be open to further change.
You may also be interested in...
The decision doesn’t directly impact manufacturers or the 340B discounts they are required to provide – and does not address the potentially much broader regulatory issue of whether the Supreme Court’s so-called Chevron doctrine should be changed.
Case before high court involving Medicare payment to hospitals for discounted outpatient drugs does not directly involve manufacturers. But the scope of the ruling could have a profound effect on how much leeway the government has to address drug pricing using administrative tools.
Linking clinical superiority to payments is another recommendations on Medicare reimbursement for separately payable drugs in the hospital outpatient prospective payment system under consideration by the Medicare Payment Advisory Commission.